March 19, 2021
Incyte Announces Results from the Phase 3 DEVENT Study Evaluating Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) on Mechanical Ventilation
– Improvement in mortality for each dose compared to placebo, while trending toward positive, was not statistically significant for the overall study population
– Significant improvement in mortality seen in U.S. study participants at both doses, and…